Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators

This article was originally published in The Pink Sheet Daily

Executive Summary

With 15 programs in various stages of early development, the Swiss biotech ratchets up the emphasis on partnering to gain back support and non-dilutive capital after the failure of its lead compound.
Advertisement

Related Content

Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million
Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing
Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing
Safety Concerns Doom Addex's Lead ADX10059 On Eve of Partnership
Safety Concerns Doom Addex's Lead ADX10059 On Eve of Partnership
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery

Topics

Advertisement
UsernamePublicRestriction

Register

PS070625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel